Navigation Links
Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
Date:4/29/2009

New Screening Test Will Focus on 4.3 Million Annual U.S. Birth Market

SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN) and Entest BioMedical Inc., BMSN's wholly-owned subsidiary, today announced that a contract has been signed with Dr. Brian Koos, a professor of Obstetrics and Gynecology at the David Geffen School of Medicine at UCLA for the development, refinement, and validation of a screening test for gestational diabetes, a glucose intolerance in pregnant women. Dr. Koos is the developer of a screening test for gestational diabetes licensed to Entest BioMedical by UCLA. The screening test mitigates the lengthy process of diagnosing gestational diabetes and would allow for faster treatment of the disease. Entest is the exclusive licensee for Dr. Koos' gestational diabetes screening test. Both companies stated that their goal is to develop a large scale sampling for validation of the screening test with Food and Drug Administration. The gestational diabetes screening test would be marketed to hospitals and medical clinics. The U.S. Dept. of Health and Human Services recently reported that there are approximately 4.3 million live births in the U.S.

According to Dr. Koos, "There is a very large potential market for our screening test. Gestational diabetes is diabetes that is found for the first time when a woman is pregnant. Out of every 100 pregnant women in the U.S., three to eight get gestational diabetes. Diabetes means your blood glucose (or blood sugar) is too high. The body uses glucose for energy, but too much glucose in the blood can be harmful. An additional concern is that untreated or uncontrolled gestational diabetes can result in serious problems for your baby, such as being born very large and with extra fat. Such large infants are predisposed to birth injury and to obesity later in life. This non-invasive screening test for gestational diabetes, which is very reliable, is highly accurate in identifying women with gestational diabetes."

About Bio-Matrix Scientific Group Inc.:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a San Diego, California based biotechnology research and development company with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

About Entest BioMedical Inc.:

Entest BioMedical Inc. is a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. The Company is involved with the development of testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Thomson Scientific Predicts Nobel Laureates
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. Thomson Scientific Announces BONDplus for Biological Researchers
5. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
6. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
7. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
8. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
9. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
10. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
11. Delta Dental Plans Association Forms National Scientific Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dianne Michael Insurance Agency, an ... County, is embarking on a charity drive with the aim of generating support ... orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers also ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... consulting services to residential and commercial clients in the northern Alabama and Georgia ... Nobis Works. , Since 1977, Nobis Works has built a network of support ...
(Date:12/7/2016)... ... ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than 30 ... sealed, LED luminaire that meets the needs of everyone in the patient room by ... , A 2’ x 4’ model features four modes: reading, ambient, standard and high ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e lançamento ... do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by ... , , ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
(Date:12/8/2016)... , Dec. 8, 2016 A Small Business ... National Institutes of Health (NIH) to Phoenix ... The grant will seek to determine ... device, which utilizes electromagnetic waves to treat Alzheimer,s Disease. ... novel technology to possibly treat other neurologic disorders such ...
Breaking Medicine Technology: